Catalog

Family and mechanism overview

Combinations by mechanism

Choose a category to see PHI-rated combinations. The numbers show how many combinations are in each list.

How to read the table

0 means the category is not marked in the review. ? N means the mechanism’s contribution is uncertain for N combinations. A combination may appear in several columns; it is counted once in the overall total.

Combinations by mechanism
Substance groups Sero­tonin-related Cardio­vascular and thermal Sedation and respi­ration Metab­olism NMDA Anti­musca­rinic Seizure-related concern Other discussed pathways
MAO inhibitors 7 entries 7 This category is not marked in the review This category is not marked in the review 1 This category is not marked in the review This category is not marked in the review This category is not marked in the review This category is not marked in the review
Antidepressants 7 entries 7 3 1 3 This category is not marked in the review 1 This category is not marked in the review This category is not marked in the review
Stimulants 10 entries 5 The mechanism’s contribution is uncertain for 1 combination 10 This category is not marked in the review 1 This category is not marked in the review This category is not marked in the review This category is not marked in the review This category is not marked in the review
Opioids and opioid-like agents 9 entries 5 The mechanism’s contribution is uncertain for 1 combination 2 9 3 The mechanism’s contribution is uncertain for 1 combination This category is not marked in the review This category is not marked in the review 2 This category is not marked in the review
Other depressants 9 entries This category is not marked in the review This category is not marked in the review 9 This category is not marked in the review This category is not marked in the review This category is not marked in the review This category is not marked in the review This category is not marked in the review
Dissociatives 5 entries This category is not marked in the review 2 1 This category is not marked in the review 5 This category is not marked in the review This category is not marked in the review 2 The mechanism’s contribution is uncertain for 1 combination
Psychedelics 8 entries 7 5 1 This category is not marked in the review This category is not marked in the review This category is not marked in the review 1 1
Cannabinoids 2 entries This category is not marked in the review 1 This category is not marked in the review 1 This category is not marked in the review This category is not marked in the review This category is not marked in the review 2
Antihistamines and antiemetics 7 entries 1 This category is not marked in the review 6 The mechanism’s contribution is uncertain for 1 combination 1 The mechanism’s contribution is uncertain for 1 combination This category is not marked in the review 5 This category is not marked in the review This category is not marked in the review
Other metabolic modifiers 6 entries This category is not marked in the review 1 This category is not marked in the review 6 This category is not marked in the review This category is not marked in the review 1 This category is not marked in the review
Total rated entries 32 entries 24 entries 27 entries 16 entries 5 entries 6 entries 4 entries 5 entries
MAO inhibitors: 7 entries

MAO inhibitors

Antidepressants: 7 entries

Antidepressants

Stimulants: 10 entries

Stimulants

Opioids and opioid-like agents: 9 entries

Opioids and opioid-like agents

Other depressants: 9 entries

Other depressants

Dissociatives: 5 entries

Dissociatives

Psychedelics: 8 entries

Psychedelics

Cannabinoids: 2 entries

Cannabinoids

Antihistamines and antiemetics: 7 entries

Antihistamines and antiemetics

Other metabolic modifiers: 6 entries

Other metabolic modifiers

Total rated entries
  • Serotonin-related: 32 entries
  • Cardiovascular and thermal: 24 entries
  • Sedation and respiration: 27 entries
  • Metabolism: 16 entries
  • NMDA: 5 entries
  • Antimuscarinic: 6 entries
  • Seizure-related concern: 4 entries
  • Other discussed pathways: 5 entries

Total: 70 rated entries

Entry count
  1. 0
  2. 5
  3. 10

Expand a substance group to see its coloured counts.

Total: 70 rated entries

Entries without a PHI rating: 14

Interaction catalog

Confidence in direct evidence

Found: 84 interactions

All available entries; no filters applied.

Overlapping ranges: the ordering by hazard level remains uncertain

PHI color scale

  1. 0
  2. 1–2
  3. 3–4
  4. 5–6
  5. 7–8
  6. 9
  7. 10

MAO inhibitors

DXM + Harmine, harmaline, Syrian rue, ayahuasca, harmala-containing changa

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 8 to 9
Compare
Details

The concern rests on MAO-A inhibition by harmala components. The directory has a dedicated entry for DMT without MAOIs [9].

MAO — Monoamine oxidase
ⓘ

MAO — monoamine oxidase

An enzyme involved in breaking down serotonin.

Breakdown and reuptake are different processes.

Sources: MAO — monoamine oxidase

DXM + Methylene blue, intravenous

PHI 8 to 9
Compare
Details

The high rating rests on potent MAO-A inhibition and the AUVELITY contraindication [2, 41].

MAO — Monoamine oxidase
ⓘ

MAO — monoamine oxidase

An enzyme involved in breaking down serotonin.

Breakdown and reuptake are different processes.

Sources: MAO — monoamine oxidase

DXM + Moclobemide

PHI 8 to 9
Compare
Details

MAO-A inhibition plus direct human inhibition of DXM O-demethylation; fatal overdose reported [27, 43]

MAO — Monoamine oxidase
ⓘ

MAO — monoamine oxidase

An enzyme involved in breaking down serotonin.

Breakdown and reuptake are different processes.

Sources: MAO — monoamine oxidase
2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6

DXM + Other reversible MAO-A inhibitors

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 8 to 9
Compare
Details

Reversible MAO-A inhibitors retain the class mechanism of severe toxicity [2, 9].

MAO — Monoamine oxidase
ⓘ

MAO — monoamine oxidase

An enzyme involved in breaking down serotonin.

Breakdown and reuptake are different processes.

Sources: MAO — monoamine oxidase

DXM + Phenelzine, tranylcypromine, isocarboxazid

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 9
Compare
Details

MAO inhibition combined with SERT effects; severe serotonin toxicity; contraindication; historical possible fatal reaction involving phenelzine [2, 4, 42]

MAO — Monoamine oxidase
ⓘ

MAO — monoamine oxidase

An enzyme involved in breaking down serotonin.

Breakdown and reuptake are different processes.

Sources: MAO — monoamine oxidase

DXM + Selegiline or rasagiline, when MAO-B selectivity is lost

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 8 to 9
Compare
Details

MAO-A inhibition becomes relevant when selectivity is lost. This depends on the conditions of selegiline or rasagiline use [26, 34].

MAO — Monoamine oxidase
ⓘ

MAO — monoamine oxidase

An enzyme involved in breaking down serotonin.

Breakdown and reuptake are different processes.

Sources: MAO — monoamine oxidase

DXM + Linezolid

PHI 6 to 8
Compare
Details

Mild reversible MAO inhibition; negative controlled DXM interaction findings at therapeutic exposure. Concern at other exposures is mechanistic; AUVELITY contraindicates coadministration [2, 39, 40]

MAO — Monoamine oxidase
ⓘ

MAO — monoamine oxidase

An enzyme involved in breaking down serotonin.

Breakdown and reuptake are different processes.

Sources: MAO — monoamine oxidase

DXM + Selegiline, rasagiline, and safinamide, with maintained MAO-B selectivity

No PHI rating
Compare
Details

Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.

Antidepressants

DXM + Clomipramine and other tricyclic antidepressants (TCAs)

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 6 to 8
Compare
Details

Heterogeneous class; serotonergic, anticholinergic, and cardiac effects [2, 4]

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
AM — Antimuscarinic effects
ⓘ

Antimuscarinic effects, including impaired sweating and peripheral toxicity

CARD — Cardiac electrophysiology
ⓘ

Additional cardiac electrophysiological effects, including QT-related concerns where specified

DXM + Duloxetine

PHI 6 to 8
Compare
Details

SNRI effects plus CYP2D6 inhibition; limited quantitative assessment of the pair [2]

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Fluoxetine, paroxetine

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 7 to 8
Compare
Details

Serotonergic effects plus strong CYP2D6 inhibition; increased DXM exposure [2, 4]

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6

DXM + Nefazodone

PHI 5 to 7
Compare
Details

Serotonergic effects and CYP3A inhibition. Hepatotoxicity is described for nefazodone itself.

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
5HT-R — Serotonin receptors
ⓘ

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor
3A — CYP3A metabolism
ⓘ

CYP3A

A group of related CYP enzymes involved in the chemical transformation of medicines.

CYP3A is an enzyme group that includes CYP3A4 and CYP3A5.

Sources: CYP3A

DXM + Sertraline, escitalopram, citalopram, fluvoxamine

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 6 to 7
Compare
Details

Serotonin toxicity; CYP contribution varies between drugs [2, 6, 7]

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT

DXM + Venlafaxine, desvenlafaxine

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 6 to 7
Compare
Details

SERT effects and noradrenergic stress; limited direct evidence [2]

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Trazodone

PHI 4 to 6
Compare
Details

Serotonergic effects and sedation; pair-specific risk not measured

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
5HT-R — Serotonin receptors
ⓘ

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor
SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Mirtazapine

No PHI rating
Compare
Details

Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.

Stimulants

DXM + MDA, serotonergic cathinones, and other serotonergic releasers

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 7 to 9
Compare
Details

Class extrapolation; MDMA’s CYP2D6 effect cannot automatically be transferred to other substances

REL — Monoamine release
ⓘ

Neurotransmitter release

Movement of neurotransmitter molecules from a nerve ending into the space between cells.

During release a neurotransmitter leaves a nerve ending; during reuptake it returns into a cell.

Sources: Neurotransmitter release
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + MDMA

PHI 8 to 9
Compare
Details

Serotonergic and autonomic stress; marked alteration of DXM PK; *High D concerns PK [3]

REL — Monoamine release
ⓘ

Neurotransmitter release

Movement of neurotransmitter molecules from a nerve ending into the space between cells.

During release a neurotransmitter leaves a nerve ending; during reuptake it returns into a cell.

Sources: Neurotransmitter release
2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Cocaine

PHI 6 to 8
Compare
Details

Sympathetic stress, ischemia, arrhythmias, and SERT effects

SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system
SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT

DXM + Methamphetamine

PHI 6 to 8
Compare
Details

Autonomic and serotonergic stress; severity of the pair not calibrated

SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system
REL — Monoamine release
ⓘ

Neurotransmitter release

Movement of neurotransmitter molecules from a nerve ending into the space between cells.

During release a neurotransmitter leaves a nerve ending; during reuptake it returns into a cell.

Sources: Neurotransmitter release

DXM + Amphetamine, dextroamphetamine

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 5 to 7
Compare
Details

Blood pressure, heart rate, temperature; possible serotonergic contribution

SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system
REL — Monoamine release (uncertain contribution)
ⓘ

Neurotransmitter release

Movement of neurotransmitter molecules from a nerve ending into the space between cells.

During release a neurotransmitter leaves a nerve ending; during reuptake it returns into a cell.

Sources: Neurotransmitter release

DXM + Methylphenidate

PHI 4 to 6
Compare
Details

Predominantly catecholaminergic effects.

SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Yohimbine

PHI 4 to 6
Compare
Details

The rating is based on adrenergic stress. The Olney’s lesions hypothesis is part of the historical FAQ discussion [1, 21].

SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Pseudoephedrine, phenylephrine

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 3 to 5
Compare
Details

Additional cardiovascular stress; no separate quantitative study identified

SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Caffeine

PHI 1 to 3
Compare
Details

Heart rate and blood pressure; not equated with potent stimulants

SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Nicotine

PHI 1 to 3
Compare
Details

Heart rate, blood pressure and nausea. The FAQ includes reports of strong potentiation of DXM’s effects [1].

SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

Opioids and opioid-like agents

DXM + Pethidine (meperidine)

PHI 7 to 9
Compare
Details

SERT inhibition [5]; respiratory depression and seizure potential of its metabolite, with accumulation during prolonged use [52]

OP — μ-opioid effects
ⓘ

μ-opioid effects and associated respiratory hazards

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
SEIZ — An additional seizure-related concern

DXM + Tramadol

PHI 7 to 9
Compare
Details

Serotonergic effects [5]; seizures and opioid effects [51]; multiple pathways of toxicity

OP — μ-opioid effects
ⓘ

μ-opioid effects and associated respiratory hazards

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
SEIZ — An additional seizure-related concern

DXM + Fentanyl

PHI 6 to 8
Compare
Details

Primarily its own respiratory depression; a separate serotonergic signal [5]

OP — μ-opioid effects
ⓘ

μ-opioid effects and associated respiratory hazards

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

5HT-R — Serotonin receptors (uncertain contribution)
ⓘ

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor

DXM + Methadone

PHI 7 to 8
Compare
Details

Serotonergic effects [5], respiration [53], and duration (endpoint unspecified in this review); CYP2D6 inhibition shown in humans [20]

OP — μ-opioid effects
ⓘ

μ-opioid effects and associated respiratory hazards

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6
CARD — Cardiac electrophysiology
ⓘ

Additional cardiac electrophysiological effects, including QT-related concerns where specified

DXM + Morphine, hydromorphone, oxycodone, heroin

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 5 to 7
Compare
Details

The main concerns involve breathing, consciousness and material entering the airways. These opioids differ from tramadol in their effects on serotonin reuptake [5].

OP — μ-opioid effects
ⓘ

μ-opioid effects and associated respiratory hazards

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Tapentadol

PHI 5 to 7
Compare
Details

Opioid effects plus demonstrated SERT/NET inhibition; the clinical contribution of the DXM interaction remains uncertain [5]

OP — μ-opioid effects
ⓘ

μ-opioid effects and associated respiratory hazards

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Buprenorphine

PHI 4 to 6
Compare
Details

Opioid sedation — drowsiness and reduced alertness. Concerns about the DXM combination remain even when individual effects reach a ceiling [5].

OP — μ-opioid effects
ⓘ

μ-opioid effects and associated respiratory hazards

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Codeine

PHI 4 to 6
Compare
Details

Opioid effects; variable CYP2D6-mediated conversion of codeine to morphine [54, 55]

OP — μ-opioid effects
ⓘ

μ-opioid effects and associated respiratory hazards

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6

DXM + Kratom (Mitragyna speciosa)

PHI 3 to 5
Compare
Details

*A single low exposure did not alter DXM PK; sedation and other exposure conditions remain separate issues [29]

OP — μ-opioid effects (uncertain contribution)
ⓘ

μ-opioid effects and associated respiratory hazards

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

3A — CYP3A metabolism (uncertain contribution)
ⓘ

CYP3A

A group of related CYP enzymes involved in the chemical transformation of medicines.

CYP3A is an enzyme group that includes CYP3A4 and CYP3A5.

Sources: CYP3A

Other depressants

DXM + Barbiturates, including phenobarbital and pentobarbital

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 6 to 8
Compare
Details

Marked CNS and respiratory depression; pair-specific complication rate unknown [1]

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + GHB, GBL, 1,4-butanediol

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 6 to 8
Compare
Details

Coma and respiratory failure; steep concentration–effect relationship for GHB [11]

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Amanita muscaria or Amanita pantherina

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 5 to 7
Compare
Details

Muscimol, ibotenic acid and variable composition. The source describes mushroom properties and toxicity; information on the DXM combination is limited [16].

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Ethanol

PHI 4 to 6
Compare
Details

Sedation, vomiting, aspiration; neuroprotection not established [1]

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Muscimol

PHI 4 to 6
Compare
Details

GABA-A effects, impaired consciousness, aspiration [16]

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Phenibut, baclofen

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 4 to 6
Compare
Details

GABA-B effects and sedation; direct DXM interaction insufficiently studied

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Pregabalin, gabapentin

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 4 to 6
Compare
Details

Sedation, ataxia; respiratory concern increases with additional risk factors [12]

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Benzodiazepines, including alprazolam, diazepam, clonazepam

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 3 to 5
Compare
Details

Consciousness, coordination, protective reflexes; not all consequences are direct respiratory depression [1]

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Zolpidem, zopiclone, and other Z-drugs

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 3 to 5
Compare
Details

Sedation and impaired consciousness; pharmacodynamic extrapolation

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

Dissociatives

DXM + MXE and other ketamine analogues

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 4 to 7
Compare
Details

Heterogeneous group; additional monoamine effects possible for some compounds

NMDA — Overlapping NMDA-antagonist effects
ⓘ

NMDA receptor

A glutamate receptor that controls an ion channel in a cell.

An ion channel lets electrically charged particles pass.

Sources: NMDA receptor
MONO — Additional monoamine effects (uncertain contribution)
ⓘ

Variable additional monoamine effects within a heterogeneous group

DXM + PCP, 3-MeO-PCP, 3-HO-PCP, and related compounds

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 5 to 7
Compare
Details

Heterogeneous NMDA and additional effects; autonomic stress and prolonged impairment

NMDA — Overlapping NMDA-antagonist effects
ⓘ

NMDA receptor

A glutamate receptor that controls an ion channel in a cell.

An ion channel lets electrically charged particles pass.

Sources: NMDA receptor
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Ketamine

PHI 4 to 6
Compare
Details

Additive dissociation, vomiting, impaired protective reflexes, blood pressure; specific synergy not measured [14]

NMDA — Overlapping NMDA-antagonist effects
ⓘ

NMDA receptor

A glutamate receptor that controls an ion channel in a cell.

An ion channel lets electrically charged particles pass.

Sources: NMDA receptor
SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Memantine

PHI 3 to 5
Compare
Details

Overlapping NMDA effects and long duration; labeling notes lack of systematic assessment of the pair [14]

NMDA — Overlapping NMDA-antagonist effects
ⓘ

NMDA receptor

A glutamate receptor that controls an ion channel in a cell.

An ion channel lets electrically charged particles pass.

Sources: NMDA receptor

DXM + Nitrous oxide

PHI 3 to 5
Compare
Details

Dissociation plus its own hypoxia hazards; repeated use introduces a separate B12-related hazard [13]

NMDA — Overlapping NMDA-antagonist effects
ⓘ

NMDA receptor

A glutamate receptor that controls an ion channel in a cell.

An ion channel lets electrically charged particles pass.

Sources: NMDA receptor
HYPOX — Oxygen deprivation
ⓘ

Oxygen deprivation / functional vitamin B12 inactivation, principally intrinsic N2O hazards

B12 — Vitamin B12 inactivation
ⓘ

Oxygen deprivation / functional vitamin B12 inactivation, principally intrinsic N2O hazards

Psychedelics

DXM + NBOMe compounds, including 25I, 25B, 25C

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 6 to 8
Compare
Details

Their own systemic toxicity, seizures, hyperthermia; additional DXM hazard inferred [15]

5HT-R — Serotonin receptors
ⓘ

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system
SEIZ — An additional seizure-related concern

DXM + 5-MeO-DMT, without MAOIs

PHI 4 to 6
Compare
Details

Impaired consciousness and possible serotonergic contribution; principally extrapolative rating [9]

5HT-R — Serotonin receptors
ⓘ

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor
SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + DOx compounds, including DOM, DOB, DOC

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 4 to 6
Compare
Details

Prolonged autonomic and vascular stress; pair-specific risk not established

5HT-R — Serotonin receptors
ⓘ

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + 2C-B

PHI 2 to 4
Compare
Details

Receptor-mediated psychedelic with autonomic effects; MDMA PK findings cannot be transferred [1]

5HT-R — Serotonin receptors
ⓘ

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + DMT, without MAOIs

PHI 2 to 4
Compare
Details

Acute autonomic effects and impairment; little direct DXM evidence [8]

5HT-R — Serotonin receptors
ⓘ

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + Mescaline

PHI 2 to 4
Compare
Details

More prominent nausea and autonomic stress; not the MDMA mechanism [8]

5HT-R — Serotonin receptors
ⓘ

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor
SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

DXM + LSD, psilocybin, psilocin

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 1 to 3
Compare
Details

Direct organ toxicity of the interaction not established; vomiting and autonomic effects possible [1, 8]

5HT-R — Serotonin receptors
ⓘ

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor

DXM + Salvinorin A (Salvia divinorum)

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 1 to 3
Compare
Details

Specific toxic synergy not established; functional impairment and secondary physical hazards [17]

KOR — κ-opioid effects
ⓘ

KOR — κ-opioid receptor

One type of opioid receptor.

κ and μ are labels for different types of opioid receptor.

Sources: KOR — κ-opioid receptor
IMP — Functional impairment
ⓘ

Cannabinoid-related effects / functional impairment and secondary physical hazards

Cannabinoids

DXM + THC-dominant cannabis

PHI 2 to 4
Compare
Details

Heart rate, vomiting, coordination; much of the potentiation is subjective [1, 10]

CB — Cannabinoid-related effects
ⓘ

Cannabinoid-related effects / functional impairment and secondary physical hazards

SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system
IMP — Functional impairment
ⓘ

Cannabinoid-related effects / functional impairment and secondary physical hazards

DXM + CBD-dominant products

PHI 1 to 3
Compare
Details

*Direct PK evidence limited to a specific study; marked CYP2D6 inhibition not found [10]

CYP — CYP metabolism
ⓘ

CYP

A family of enzymes involved in chemically transforming drugs.

Metabolism can reduce or increase a substance’s activity.

Sources: CYP
CB — Cannabinoid-related effects
ⓘ

Cannabinoid-related effects / functional impairment and secondary physical hazards

Antihistamines and antiemetics

DXM + Chlorphenamine (chlorpheniramine)

PHI 6 to 7
Compare
Details

SERT and anticholinergic effects; poisonings involving combination products [6]

SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT
AM — Antimuscarinic effects
ⓘ

Antimuscarinic effects, including impaired sweating and peripheral toxicity

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Diphenhydramine, dimenhydrinate, doxylamine

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 4 to 6
Compare
Details

Sedation and anticholinergic effects; CYP2D6 contribution better supported for diphenhydramine [18]

AM — Antimuscarinic effects
ⓘ

Antimuscarinic effects, including impaired sweating and peripheral toxicity

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

2D6 — CYP2D6 metabolism (uncertain contribution)
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6

DXM + Scopolamine, with known active-substance exposure

PHI 4 to 6
Compare
Details

Antimuscarinic effects, hyperthermia, impairment, not a DXM trial [32]

AM — Antimuscarinic effects
ⓘ

Antimuscarinic effects, including impaired sweating and peripheral toxicity

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Cyclizine, meclizine, hydroxyzine

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 3 to 5
Compare
Details

Sedative and anticholinergic effects differ, not established severity of each pair

AM — Antimuscarinic effects
ⓘ

Antimuscarinic effects, including impaired sweating and peripheral toxicity

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Promethazine

PHI 3 to 5
Compare
Details

*Therapeutic DXM combination and labeling; sedation, respiratory and anticholinergic concerns [33]

AM — Antimuscarinic effects
ⓘ

Antimuscarinic effects, including impaired sweating and peripheral toxicity

SED — Sedation
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Loratadine, desloratadine, cetirizine

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 1 to 3
Compare
Details

Sedation varies across this group; concerns depend on the individual drug.

SED — Sedation (uncertain contribution)
ⓘ

Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences

DXM + Fexofenadine

PHI 1 to 2
Compare
Details

No substantial toxic mechanism of the pair identified; direct proof of safety absent

No interaction mechanism identified

DXM + Ondansetron

No PHI rating
Compare
Details

Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.

Other metabolic modifiers

DXM + Quinidine

PHI 6 to 8
Compare
Details

*Direct PK evidence; additional QT and arrhythmia concerns depend on conditions [4, 19]

2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6
CARD — Cardiac electrophysiology
ⓘ

Additional cardiac electrophysiological effects, including QT-related concerns where specified

DXM + Bupropion

PHI 5 to 7
Compare
Details

*Established increase in DXM exposure; its own seizure hazard [2]

2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6
SEIZ — An additional seizure-related concern

Also belongs to: Antidepressants

DXM + Other strong CYP3A inhibitors, including cobicistat, azoles, clarithromycin

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 3 to 6
Compare
Details

Reduced alternative metabolism; heterogeneous effects [24]

3A — CYP3A metabolism
ⓘ

CYP3A

A group of related CYP enzymes involved in the chemical transformation of medicines.

CYP3A is an enzyme group that includes CYP3A4 and CYP3A5.

Sources: CYP3A

DXM + Ritonavir, alone or in ritonavir-boosted regimens

PHI 3 to 6
Compare
Details

*Direct human metabolic-probe data differ between regimens and endpoints; not a uniform strong CYP2D6 effect [45, 46]

3A — CYP3A metabolism
ⓘ

CYP3A

A group of related CYP enzymes involved in the chemical transformation of medicines.

CYP3A is an enzyme group that includes CYP3A4 and CYP3A5.

Sources: CYP3A
2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6

DXM + Terbinafine, oral

PHI 4 to 6
Compare
Details

*Direct metabolic-phenotyping evidence of CYP2D6 inhibition. High confidence H concerns that measured endpoint [23].

2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6

DXM + Grapefruit and Seville orange juice

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 2 to 4
Compare
Details

*DXM PK changes shown; clinical importance depends on metabolism [22]

3A — CYP3A metabolism
ⓘ

CYP3A

A group of related CYP enzymes involved in the chemical transformation of medicines.

CYP3A is an enzyme group that includes CYP3A4 and CYP3A5.

Sources: CYP3A

Other agents and products

DXM + 5-HTP

No PHI rating
Compare
Details

Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.

DXM + buspirone

No PHI rating
Compare
Details

Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.

DXM + Combination medicines containing acetaminophen (paracetamol)

No PHI rating
Compare
Details

DXM alone must be distinguished from combination medicines. Acetaminophen (paracetamol), chlorphenamine, sedating antihistamines, and sympathomimetic decongestants can create their own toxicity when more of the product is taken. These ingredients place the product outside most two-substance rows [6, 7, 25]. Extended-release formulations also alter the duration of overlapping effects.

DXM + cyclobenzaprine

No PHI rating
Compare
Details

Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.

DXM + Datura and Atropa belladonna

No PHI rating
Compare
Details

Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.

DXM + Lithium

No PHI rating
Compare
Details

Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.

DXM + Piracetam, DMAE, and lecithin

No PHI rating
Compare
Details

Piracetam, DMAE, and lecithin are excluded from the numerical matrix. The FAQ contains accounts of subjective memory improvement, but evidence is insufficient to treat them as protection against physical injury.

DXM + QT-prolonging drugs

No PHI rating
Compare
Details

Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.

DXM + St John’s wort

No PHI rating
Compare
Details

Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.

DXM + triptans

No PHI rating
Compare
Details

Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.

DXM + tryptophan

No PHI rating
Compare
Details

Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.

Reference

Open the source and related combinations →